Drugs News and Research

RSS

Clinical trials will help to develop treatment and follow-up of COPD patients

Three major clinical trials will help to develop and target treatment and follow-up of patients suffering from COPD, lung cancer and rheumatoid arthritis in Norway.

22 Oct 2013

NeuroAiD reduces early cardiovascular events and deaths by 50% after stroke onset

NeuroAiD™, a treatment of post-stroke recovery containing natural extracts, reduces early cardiovascular events and deaths by nearly 50% on top of antiplatelet agents within three months after stroke onset, without an increase in bleeding rate and non-vascular deaths according to research published online in the journal Stroke.

22 Oct 2013

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in patients with recurrent high-grade glioma.

22 Oct 2013

Breast milk may protect babies from acquiring HIV infection, say researchers

A substance in breast milk that neutralizes HIV and may protect babies from acquiring HIV from their infected mothers has been identified for the first time by researchers at Duke Medicine.

22 Oct 2013

Study opens doors to novel treatments for aggressive brain cancer

Ludwig researchers have elucidated a key mechanism by which cancer cells change how they metabolize glucose to generate the energy and raw materials required to sustain runaway growth.

22 Oct 2013

Pancreatic cancer patients may benefit from antibody-drug conjugates

Patients with pancreatic cancer may benefit from an investigational member of an emerging class of anticancer drugs called antibody-drug conjugates, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved a subcutaneous formulation of Actemra (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis who have used one or more disease-modifying antirheumatic drugs, such as methotrexate, that did not provide enough relief.

22 Oct 2013

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

UCLA receives $7M grant to investigate links between substance abuse and HIV among minority men

The National Institute on Drug Abuse has awarded UCLA a $7 million grant to investigate the links between substance abuse and HIV among Latino and African-American men who have sex with men.

22 Oct 2013

SPARC announces award recipients for Accelerating Science Award Program

The three award recipients for the Accelerating Science Award Program (ASAP) were announced today in Washington, DC at the Open Access Week kickoff event hosted by the Scholarly Publishing and Academic Resources Coalition (SPARC) and the World Bank.

22 Oct 2013

Scientist receives NIH New Innovator Award to design innovative approaches for cancer treatment

Derek Taylor, PhD, a member of the Case Western Reserve School of Medicine, has been awarded the prestigious New Innovator Award by the National Institutes of Health (NIH).

22 Oct 2013

Astrazeneca, Evotec Launch Kidney Disease Collaboration

...

21 Oct 2013

Research paper published by Scientific Reports details the efficacy of n3D's Apple iPhone app

Joint venture partners Rainbow Coral Corp. and Nano3D Biosciences (n3D) are proud to announce that the journal Scientific Reports published the first research document detailing the efficacy of n3D's revolutionary new Apple iPhone app today.

21 Oct 2013

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

Regeneron Pharmaceuticals, Inc. today announced positive topline results for EYLEA® (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO).

21 Oct 2013

DOH releases SPHHS study investigating prescribing of antipsychotics to District seniors

The District of Columbia Department of Health has released a study by the George Washington University School of Public Health and Health Services investigating prescribing of antipsychotics to District seniors.

21 Oct 2013

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced positive results from the Phase 1 portion of its Phase 1/1b study of defactinib (VS-6063) in combination with paclitaxel in patients with ovarian cancer that were presented at the 2013 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.

21 Oct 2013

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

NanoViricides, Inc. (the "Company") reports that its optimized injectable FluCide® drug candidate was found to be well tolerated in a non-GLP small animal safety/toxicology study. This study is an important step in the drug development pathway for FluCide.

21 Oct 2013

New collaborative project aims to discover genes underlying rare genetic diseases

...

21 Oct 2013

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Oct 2013

Drugs News and Research

Clinical trials will help to develop treatment and follow-up of COPD patients

NeuroAiD reduces early cardiovascular events and deaths by 50% after stroke onset

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma

Breast milk may protect babies from acquiring HIV infection, say researchers

Study opens doors to novel treatments for aggressive brain cancer

Pancreatic cancer patients may benefit from antibody-drug conjugates

FDA approves SC formulation of Genentech's Actemra for rheumatoid arthritis

Two drug combinations may provide new treatment option for patients with pancreatic cancers

UCLA receives $7M grant to investigate links between substance abuse and HIV among minority men

SPARC announces award recipients for Accelerating Science Award Program

Scientist receives NIH New Innovator Award to design innovative approaches for cancer treatment

Astrazeneca, Evotec Launch Kidney Disease Collaboration

Research paper published by Scientific Reports details the efficacy of n3D's Apple iPhone app

Regeneron announces topline results from Phase 3 study of EYLEA Injection in patients with Macular Edema following BRVO

DOH releases SPHHS study investigating prescribing of antipsychotics to District seniors

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

NanoViricides’ FluCide drug candidate found to be well tolerated in non-GLP safety/toxicology study

New collaborative project aims to discover genes underlying rare genetic diseases

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Industry Focus eBook - Cell biology (5th edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News